JP2012530782A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012530782A5 JP2012530782A5 JP2012517634A JP2012517634A JP2012530782A5 JP 2012530782 A5 JP2012530782 A5 JP 2012530782A5 JP 2012517634 A JP2012517634 A JP 2012517634A JP 2012517634 A JP2012517634 A JP 2012517634A JP 2012530782 A5 JP2012530782 A5 JP 2012530782A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- group
- thiol
- refolding
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000018102 proteins Nutrition 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 150000003573 thiols Chemical class 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 239000011159 matrix material Substances 0.000 claims 4
- 238000000926 separation method Methods 0.000 claims 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 3
- 238000002955 isolation Methods 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- RMOYURUHGCBZCX-UHFFFAOYSA-L dipotassium;sodium;sulfate Chemical compound [Na].[K+].[K+].[O-]S([O-])(=O)=O RMOYURUHGCBZCX-UHFFFAOYSA-L 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000002563 ionic surfactant Substances 0.000 claims 2
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 230000000065 osmolyte Effects 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 2
- 235000011152 sodium sulphate Nutrition 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 1
- 229940099500 Cystamine Drugs 0.000 claims 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N Cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 1
- 229940119025 Cysteamine Drugs 0.000 claims 1
- 229960002433 Cysteine Drugs 0.000 claims 1
- 229960003067 Cystine Drugs 0.000 claims 1
- 108010053070 Glutathione Disulfide Proteins 0.000 claims 1
- 210000003000 Inclusion Bodies Anatomy 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine zwitterion Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 1
- 229960003151 Mercaptamine Drugs 0.000 claims 1
- MGJKQDOBUOMPEZ-UHFFFAOYSA-N N,N'-dimethylurea Chemical compound CNC(=O)NC MGJKQDOBUOMPEZ-UHFFFAOYSA-N 0.000 claims 1
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methyl urea Chemical compound CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 230000001580 bacterial Effects 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 238000011118 depth filtration Methods 0.000 claims 1
- RYECOJGRJDOGPP-UHFFFAOYSA-N ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical class NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 claims 1
- 238000005342 ion exchange Methods 0.000 claims 1
- 239000012562 protein A resin Substances 0.000 claims 1
- 239000006176 redox buffer Substances 0.000 claims 1
Claims (15)
- リフォールディングの最中に、
(a)0.001〜100の範囲を有する最終的なチオール対比および2mM以上のチオール対緩衝液強度を含むレドックス成分と、
(i)変性剤;
(ii)凝集抑制剤;および
(iii)タンパク質安定化剤、
のうちの1種以上と、を含むリフォールディング緩衝液にタンパク質を接触させて、リフォールディング混合物を形成させること
〔ここで、チオール対比は、式1:
レドックス緩衝液強度は、式2:
(b)前記リフォールディング混合物をインキュベートすること;並びに
(c)前記リフォールディング混合物から前記タンパク質を単離すること
を含む、非哺乳類発現系中に発現された、2.0g/L以上の濃度で多量に存在する複合多量体タンパク質をリフォールディングする方法。 - 前記最終的なチオール対比が、0.05〜50、0.1〜50、0.25〜50、0.5〜50、0.75〜40、1.0〜50または1.5〜50、2〜50、5〜50、10〜50、15〜50、20〜50、30〜50または40〜50からなる群より選択される、請求項1に記載の方法。
- 前記チオール対緩衝液強度が、2.25mM以上、2.5mM以上、2.75mM以上、3mM以上、5mM以上、7.5mM以上、10mM以上または15mM以上からなる群より選択される、請求項1に記載の方法。
- 前記タンパク質が、
(i)非天然の難溶性形態、好ましくは封入体、または
(ii)可溶性形態
で存在する、請求項1に記載の方法。 - 前記タンパク質が、組換え体、内在性タンパク質、抗体、またはFc−タンパク質結合体である、請求項1に記載の方法。
- 前記非哺乳類発現系が、細菌発現系および酵母発現系のうちの1つである、請求項1に記載の方法。
- 前記変性剤が、尿素、グアニジニウム塩、ジメチル尿素、メチル尿素およびエチル尿素からなる群より選択される、請求項1に記載の方法。
- 前記タンパク質安定化剤が、アルギニン、プロリン、ポリエチレングリコール、非イオン性界面活性剤、イオン性界面活性剤、多価アルコール、グリセロール、スクロース、ソルビトール、グルコース、トリス、硫酸ナトリウム、硫酸カリウムおよびオスモライトからなる群より選択される、請求項1に記載の方法。
- 前記凝集抑制剤が、アルギニン、プロリン、ポリエチレングリコール、非イオン性界面活性剤、イオン性界面活性剤、多価アルコール、グリセロール、スクロース、ソルビトール、グルコース、トリス、硫酸ナトリウム、硫酸カリウムおよびオスモライトからなる群より選択される、請求項1に記載の方法。
- 前記チオール対が、還元型グルタチオン、酸化型グルタチオン、システイン、シスチン、システアミン、シスタミンおよびβ−メルカプトエタノールからなる群より選択される成分を少なくとも1種含む、請求項1に記載の方法。
- 前記インキュベーションが、無酸素条件下で実施される、請求項1に記載の方法。
- 前記単離が、混合物とアフィニティー分離マトリックスとの接触を含む、請求項1に記載の方法。
- 前記アフィニティー分離マトリックスが、プロテインA樹脂、または混合方式の分離マトリックスである、請求項12に記載の方法。
- 前記単離が、混合物とイオン交換分離マトリックスとの接触を含む、請求項1に記載の方法。
- 前記単離が、さらにろ過ステップを含み、前記ろ過ステップが、好ましくは深層ろ過を含む、請求項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21925709P | 2009-06-22 | 2009-06-22 | |
US61/219,257 | 2009-06-22 | ||
PCT/US2010/039390 WO2011005488A1 (en) | 2009-06-22 | 2010-06-21 | Refolding proteins using a chemically controlled redox state |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015175422A Division JP6026608B2 (ja) | 2009-06-22 | 2015-09-07 | 化学的に制御されたレドックス状態を用いたタンパク質のリフォールディング |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012530782A JP2012530782A (ja) | 2012-12-06 |
JP2012530782A5 true JP2012530782A5 (ja) | 2013-07-18 |
JP5808323B2 JP5808323B2 (ja) | 2015-11-10 |
Family
ID=42710673
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012517634A Active JP5808323B2 (ja) | 2009-06-22 | 2010-06-21 | 化学的に制御されたレドックス状態を用いたタンパク質のリフォールディング |
JP2015175422A Active JP6026608B2 (ja) | 2009-06-22 | 2015-09-07 | 化学的に制御されたレドックス状態を用いたタンパク質のリフォールディング |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015175422A Active JP6026608B2 (ja) | 2009-06-22 | 2015-09-07 | 化学的に制御されたレドックス状態を用いたタンパク質のリフォールディング |
Country Status (15)
Country | Link |
---|---|
US (5) | US8952138B2 (ja) |
EP (2) | EP3366692A1 (ja) |
JP (2) | JP5808323B2 (ja) |
KR (1) | KR101741859B1 (ja) |
CN (1) | CN102482321B (ja) |
AU (1) | AU2010270986B2 (ja) |
BR (1) | BRPI1011940B8 (ja) |
CA (1) | CA2765881C (ja) |
CL (1) | CL2011003278A1 (ja) |
EA (1) | EA020621B1 (ja) |
IL (1) | IL216954A (ja) |
MX (1) | MX2011013898A (ja) |
SG (1) | SG176963A1 (ja) |
WO (1) | WO2011005488A1 (ja) |
ZA (1) | ZA201200512B (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3366692A1 (en) * | 2009-06-22 | 2018-08-29 | Amgen, Inc | Refolding proteins using a chemically controlled redox state |
EP2445924B2 (en) | 2009-06-25 | 2023-12-13 | Amgen Inc. | Capture purification processes for proteins expressed in a non-mammalian system |
EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
US20150376228A1 (en) * | 2013-02-22 | 2015-12-31 | Biogenomics Limited | Process for high efficiency refolding of recombinant proteins |
US10633414B2 (en) * | 2015-07-27 | 2020-04-28 | Purdue Research Foundation | Tandem folding methods to improve protein folding yield |
EP3344651B1 (en) | 2015-09-02 | 2022-03-02 | Merck Sharp & Dohme Corp. | A process for obtaining insulin with correctly formed disulfide bonds |
US11312745B2 (en) * | 2016-07-22 | 2022-04-26 | Amgen Inc. | Methods of purifying Fc-containing proteins |
CN108276470A (zh) * | 2017-01-06 | 2018-07-13 | 深圳市新产业生物医学工程股份有限公司 | 细胞裂解液、提取胞内蛋白的方法、制备弓形虫抗原的方法和试剂盒 |
US11406576B2 (en) | 2017-04-10 | 2022-08-09 | Kao Corporation | Method for removing keratotic plugs |
CN111902720A (zh) | 2018-03-21 | 2020-11-06 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
WO2020097394A1 (en) * | 2018-11-07 | 2020-05-14 | Applied Molecular Transport Inc. | Delivery constructs for transcytosis and related methods |
EP4263568A1 (en) | 2020-12-18 | 2023-10-25 | Richter Gedeon Nyrt. | Methods for the purification of refolded fc-peptide fusion protein |
CN115894604B (zh) * | 2022-12-16 | 2024-01-23 | 康日百奥生物科技(苏州)有限公司 | 重组蛋白澄清纯化方法 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4468464A (en) | 1974-11-04 | 1984-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Biologically functional molecular chimeras |
US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
GB2138004B (en) | 1983-03-25 | 1987-05-13 | Celltech Ltd | A process for the production of a protein |
US4468454A (en) | 1983-06-10 | 1984-08-28 | E. I. Du Pont De Nemours And Company | Antifoggant process |
US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
IL86090A (en) | 1987-04-16 | 1993-03-15 | Cetus Oncology Corp | Production of purified, biologically active, bacterially produced recombinant human csf-1 |
GB8807673D0 (en) | 1988-03-31 | 1988-05-05 | Lingner & Fischer Gmbh | Novel article |
EP0347041A3 (en) | 1988-05-13 | 1990-11-22 | Amgen Inc. | Compositions and method for treating or preventing infections in animals |
GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
ES2119779T3 (es) * | 1990-09-05 | 1998-10-16 | Southern Cross Biotech Pty Ltd | Solubilizacion de proteinas en formas activas. |
WO1993018136A1 (en) | 1992-03-05 | 1993-09-16 | Cytomed, Inc. | Process for supporting hematopoietic progenitor cells |
US5663304A (en) | 1993-08-20 | 1997-09-02 | Genentech, Inc. | Refolding of misfolded insulin-like growth factor-I |
ATE147753T1 (de) | 1993-11-10 | 1997-02-15 | Pfizer | Prozess zur rückfaltung von (pro-)chymosin, unter rückführung von harnstoff |
US5466377A (en) | 1994-01-19 | 1995-11-14 | Grandics; Peter | Chromatography media and their uses |
AU2603995A (en) | 1994-05-25 | 1995-12-18 | University Of Nebraska Board Of Regents | Biologically active glycoprotein hormones produced in procaryotic cells |
AU6028396A (en) | 1995-06-07 | 1996-12-30 | Amgen, Inc. | Ob protein compositions and method |
US5935824A (en) | 1996-01-31 | 1999-08-10 | Technologene, Inc. | Protein expression system |
US6653098B1 (en) * | 1998-02-23 | 2003-11-25 | G. D. Searle & Co. | Method of producing mouse and human endostatin |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
DE60024997T2 (de) | 1999-07-21 | 2006-08-24 | Amgen Inc., Thousand Oaks | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
IL152804A0 (en) | 2000-05-16 | 2003-06-24 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
US7153669B2 (en) | 2000-09-05 | 2006-12-26 | Amgen Inc. | Nucleic acids encoding MK61 receptors |
EE200300408A (et) | 2001-02-23 | 2003-12-15 | Immunex Corporation | Aktiivsete valkude saagise suurendamine |
US6972327B1 (en) | 2001-05-08 | 2005-12-06 | Immunex Corporation | Regeneration of chromatography material |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
AU2002345829A1 (en) | 2002-06-24 | 2004-01-06 | Dr. Reddy's Laboratories Ltd. | Process for preparing g-csf |
SI1581649T1 (sl) * | 2002-12-20 | 2011-09-30 | Amgen Inc | Vezna sredstva, ki zavirajo miostatin |
EP1449848A1 (en) | 2003-02-20 | 2004-08-25 | GBF German Research Centre for Biotechnology | Method for the production of cystine-knot proteins |
US20050209441A1 (en) | 2004-03-22 | 2005-09-22 | Lile Jackson D | Process for promoting proper folding of human serum albumin using a human serum albumin ligand |
FR2874318B1 (fr) | 2004-08-19 | 2006-11-24 | Oreal | Utilisation en cosmetique de composes polysaccharidiques amphoteres a chaine(s) polymerique(s) cationique(s) |
JP5017116B2 (ja) | 2004-09-24 | 2012-09-05 | アムジエン・インコーポレーテツド | 修飾Fc分子 |
US7435804B2 (en) | 2004-10-19 | 2008-10-14 | Phage Biotechnology, Inc. | Method for obtaining single chain antibodies to human interferon α2b |
NZ554520A (en) | 2004-10-22 | 2010-03-26 | Amgen Inc | Methods for refolding of recombinant antibodies |
AU2006207945B2 (en) | 2005-01-28 | 2012-02-09 | Zymogenetics, Inc. | Homogeneous preparations of IL-31 |
DE102005033250A1 (de) | 2005-07-15 | 2007-01-18 | Bioceuticals Arzneimittel Ag | Verfahren zur Reinigung von G-CSF |
MY143274A (en) | 2005-12-22 | 2011-04-15 | Genentech Inc | Recombinant production of heparin binding proteins |
US7612273B2 (en) * | 2006-03-20 | 2009-11-03 | Roland Corporation | Electronic percussion instrument |
EP1845103B1 (en) * | 2006-04-10 | 2015-02-25 | Boehringer Ingelheim RCV GmbH & Co KG | Method for refolding a protein |
TWI476207B (zh) | 2006-07-14 | 2015-03-11 | Genentech Inc | 重組蛋白之再摺疊 |
WO2008096370A2 (en) | 2007-02-05 | 2008-08-14 | Natco Pharma Limited | An efficient and novel purification method of recombinant hg-csf |
WO2008100578A2 (en) | 2007-02-14 | 2008-08-21 | Amgen Inc. | Method of isolating antibodies by precipitation |
JP2010536341A (ja) | 2007-08-15 | 2010-12-02 | アムニクス, インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
DK3216803T3 (da) | 2008-06-25 | 2020-06-02 | Novartis Ag | Stabile og opløselige antistoffer, der hæmmer vegf |
EP3366692A1 (en) | 2009-06-22 | 2018-08-29 | Amgen, Inc | Refolding proteins using a chemically controlled redox state |
EP2445924B2 (en) * | 2009-06-25 | 2023-12-13 | Amgen Inc. | Capture purification processes for proteins expressed in a non-mammalian system |
JP2016516064A (ja) | 2013-03-15 | 2016-06-02 | アムジェン インコーポレイテッド | ヒト対象におけるミオスタチンの拮抗 |
-
2010
- 2010-06-21 EP EP18167168.6A patent/EP3366692A1/en active Pending
- 2010-06-21 AU AU2010270986A patent/AU2010270986B2/en active Active
- 2010-06-21 SG SG2011095411A patent/SG176963A1/en unknown
- 2010-06-21 CA CA2765881A patent/CA2765881C/en active Active
- 2010-06-21 JP JP2012517634A patent/JP5808323B2/ja active Active
- 2010-06-21 EP EP10747092.4A patent/EP2445923B1/en active Active
- 2010-06-21 EA EA201270015A patent/EA020621B1/ru not_active IP Right Cessation
- 2010-06-21 CN CN201080028756.7A patent/CN102482321B/zh active Active
- 2010-06-21 MX MX2011013898A patent/MX2011013898A/es active IP Right Grant
- 2010-06-21 US US12/820,087 patent/US8952138B2/en active Active
- 2010-06-21 WO PCT/US2010/039390 patent/WO2011005488A1/en active Application Filing
- 2010-06-21 BR BRPI1011940A patent/BRPI1011940B8/pt active IP Right Grant
- 2010-06-21 KR KR1020127001716A patent/KR101741859B1/ko active IP Right Grant
-
2011
- 2011-12-13 IL IL216954A patent/IL216954A/en active IP Right Grant
- 2011-12-22 CL CL2011003278A patent/CL2011003278A1/es unknown
-
2012
- 2012-01-20 ZA ZA2012/00512A patent/ZA201200512B/en unknown
-
2015
- 2015-01-30 US US14/611,037 patent/US20150315232A1/en not_active Abandoned
- 2015-07-07 US US14/793,590 patent/US20150329586A1/en not_active Abandoned
- 2015-09-07 JP JP2015175422A patent/JP6026608B2/ja active Active
-
2017
- 2017-02-01 US US15/422,327 patent/US9856287B2/en active Active
-
2018
- 2018-02-06 US US15/889,559 patent/US20190055281A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012530782A5 (ja) | ||
BRPI0514340A (pt) | formulações de estabilização | |
NZ629261A (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
RU2017144220A (ru) | Среда для культуры клеток, не содержащая олигопептидов | |
US11363812B2 (en) | Cell freezing medium for clinical use | |
NZ591292A (en) | Improved cell composition and methods of making the same | |
RU2008152449A (ru) | Получение гликопротеинов | |
JP2017222654A5 (ja) | ||
RU2011127913A (ru) | Составы, содержащие антитела | |
RU2011102548A (ru) | Оптимизация растворимости иммуносвязывающих средств | |
BRPI0620806B8 (pt) | complexo e composição compreendendo um peptídeo e uma molécula carga, e uso da referida composição | |
JP2019533442A5 (ja) | ||
EA020621B1 (ru) | Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния | |
KR102495546B1 (ko) | 생체분자의 수집, 안정화 및 용리를 위한 기재 및 방법 | |
AR082257A1 (es) | Composicion de inmunoglobulinas humanas concentradas, procedimiento | |
JP2015517464A5 (ja) | ||
CN105777858B (zh) | 多种抗体的复合稳定剂及其使用方法 | |
US7776619B2 (en) | Method of stabilizing pulmonary surfactant protein | |
JP2009521232A5 (ja) | ||
US9540635B2 (en) | Buffer for one-step DNA extraction | |
JP2007075102A (ja) | 昆虫細胞培養用培地 | |
JP4761337B2 (ja) | アルカリホスファターゼの安定化方法 | |
JP2008239512A (ja) | 抗体の安定化方法 | |
JP2003009857A5 (ja) | ||
CN107247144B (zh) | 一种预处理丙肝抗原的方法和检测试剂盒 |